jcp conference-coverage

Conference Coverage

Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer

06/14/2021

More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.

More than half of patients with...

06/14/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer

06/14/2021

In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.

In a large representative sample...

06/14/2021

Journal of Clinical Pathways

Conference Coverage

Cost Analysis of Biosimilar vs Reference Rituximab for Treating CLL and Other Diseases

06/10/2021

Rituximab-abbs may have more economic benefits compared to reference rituximab in patients with NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Rituximab-abbs may have more...

06/10/2021

Journal of Clinical Pathways

Conference Coverage

Real-World PARP Inhibitor Toxicities in Ovarian Cancer Consistent With Clinical Trials

06/07/2021

In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.

In routine clinical practice,...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Utilization of Second-Line Maintenance Therapy for Patients With Ovarian Cancer

06/07/2021

Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.

Fewer than half of eligible...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Treatment Patterns Following First-Line Therapy for HER2-Positive Metastatic Breast Cancer

06/07/2021

A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.

A study exploring practice...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Outcomes of Patients Receiving Alpelisib for PIK3CA-Mutated Breast Cancer

06/07/2021

Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.

Patients with breast cancer and...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for Early Breast Cancer

06/07/2021

Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.

Neoadjuvant pertuzumab,...

06/07/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC

06/02/2021

Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.

Study findings suggest adjuvant...

06/02/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma

06/02/2021

Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.

Study findings support...

06/02/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products